每经记者:陈星每经编辑:陈俊杰| 2025年1月14日 星期二 |NO.1 和黄医药肺癌新药赛沃替尼新适应症获批1月13日,中国国家药监局(NMPA)官网最新公示,和黄医药的赛沃替尼片新适应症上市申请已获得批准。赛沃替尼是一种高选择性口服MET抑制剂。根据和黄医药此前新闻稿介绍,该药本次获批用于治疗间质-上皮转化因子(MET)外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。点评:和黄医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.